About Us

LIQID Medical is a clinical-stage medical device company focusing on addressing the need for effective, long-term solutions for glaucoma treatment. We specialise in developing lifelong implants targeting glaucoma, the leading cause of irreversible blindness.

Our work centres on leveraging the retrolaminar drainage pathway, a novel approach in biotechnology for glaucoma management. By utilising this pathway, we aim to redefine the landscape of glaucoma care, offering unparalleled efficacy and quality-of-life improvements for patients.

We are developing two core devices that address the challenges of severe and refractory glaucoma. LIQID Medical is confident in transforming the lives of glaucoma patients and setting a new benchmark in ophthalmic care. QMAX: The QMAX fills a gap in the market for a highly effective glaucoma device which does not rely on the traditional subconjunctival drainage pathway.

SUPPORTED BY

Our Implants

Rendered Image

The QMAX fills a gap in the market for highly effective
glaucoma device which does not rely on the traditional
subconjunctival drainage pathway.

Rendered Image

The QFLOW harnesses the traditional fluid drainage
pathway, using innovative design to reduce surgical
operating times, costs and complications.

Re-defining the treatment of glaucoma